Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background Understanding patterns of relapse in patients who respond to antidepressant treatment can inform strategies for prevention of relapse. We aimed to identify distinct trajectories of depression severity, assess whether similar or different trajectory classes exist for patients who continued or discontinued active treatment, and test whether clinical predictors of trajectory class membership exist using pooled data from clinical trials.Methods We analysed individual patient data from four double-blind discontinuation clinical trials of duloxetine or fluoxetine versus placebo in major depression from before 2012 (n=1462). We modelled trajectories of relapse up to 26 weeks during double-blind treatment. Trajectories of depression severity, as measured by the Hamilton Depression Rating Scale score, were identified in the entire sample, and separately in groups in which antidepressants had been continued or discontinued, using growth mixture models. Predictors of trajectory class membership were assessed with weighted logistic regression.Findings We identified similar relapse trajectories and two trajectories of stable depression scores in the normal range on active medication and on placebo. Active treatment significantly lowered the odds of membership in the relapse trajectory (odds ratio 0·47, 95% CI 0·37-0·61), whereas female sex (1·56, 1·23-2·06), shorter length of time with clinical response by 1 week (1·10, 1·06-1·15), and higher Clinical Global Impression score at baseline (1·28, 1·01-1·62) increased the odds. Overall, the protective effect of antidepressant medication relative to placebo on the risk of being classified as a relapser was about 13% (33% vs 46%).Interpretation The existence of similar relapse trajectories on active medication and on placebo suggests that there is no specific relapse signature associated with antidepressant discontinuation. Furthermore, continued treatment offers only modest protection against relapse. These data highlight the need to incorporate treatment strategies that prevent relapse as part of the treatment of depression.Funding National Institutes of Health, the US Department of Veterans Affairs Alcohol Research Center, and National Center for Post-Traumatic Stress Disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Female sex was associated with a higher probability of recurrence (within patients discontinuing ADM) in one review (Gueorguieva et al., 2017) but not in four other reviews (Beshai et al., 2011; Bourgon & Kellner, 2000; Hardeveld et al., 2010; Hughes & Cohen, 2009).”
From Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis (2018) · cites this paper as Gueorguieva et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was good evidence for an association between shorter periods of time between starting ADM and reaching “clinical response”, and higher odds of subsequent relapse (for details see Supplementary Table 1) (Gueorguieva et al., 2017).”
From Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis (2018) · cites this paper as Gueorguieva et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, neurobehavioural disorders tend to be chronic and relapse even after a positive response to treatment in the short term.20,21”
From Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies indicate that between one-fifth to one-half of patients in remission from a depressive episode will suffer a recurrence within 2 years.4–10”
Experimental — accuracy not yet measuredIn the citing paper
“This relapse rate is similar to those reported in other clinical settings7,22 and in meta-analyses of RCTs,6,8 which have shown that those who remain on antidepressants following remission had relapse rates of 21% to 49%.”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Testing the number of components in a normal mixture
Lo, Y. (2001) · Biometrika · doi:10.1093/biomet/88.3.767 · Cited by 4,640
The Epidemiology of Depression Across Cultures
Kessler, R. C., & Bromet, E. J. (2013) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031912-114409 · Cited by 2,657
Analyzing developmental trajectories: A semiparametric, group-based approach.
Nagin, D. S. (1999) · Psychological Methods · doi:10.1037/1082-989x.4.2.139 · Cited by 2,346
Finite Mixture Modeling with Mixture Outcomes Using the EM Algorithm
Muthén, B., & Shedden, K. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00463.x · Cited by 1,486
Analyzing developmental trajectories of distinct but related behaviors: A group-based method.
Nagin, D. S., & Tremblay, R. E. (2001) · Psychological Methods · doi:10.1037//1082-989x.6.1.18 · Cited by 1,280
Ram, N., & Grimm, K. J. (2009) · International Journal of Behavioral Development · doi:10.1177/0165025409343765 · Cited by 1,143
Risk for recurrence in depression
Burcusa, S. L., & Iacono, W. G. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.02.005 · Cited by 1,023
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759 · cited 1×
“14/306,382 filed on June 17, 2014 (4) Arias A, Petrakis I, Krystal JH.”
BackgroundCross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud, A. M., Zotti, R. J., Shehzad, Z., Gueorguieva, R., Johnson, M. K., Trivedi, M. H., Cannon, T. D., Krystal, J. H., & Corlett, P. R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00471-x · Cited by 676
Self-citation
Cited by
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
“…imply that psilocybin may protect against relapse to an equivalent extent to daily use of an established antidepressant—as seen in discontinuation trials where responders either continue on medication (33% relapse) or transfer to placebo (46% relapse) for 6 months (Gueorguieva et al. 2017).”
BackgroundThe promise of machine learning in predicting treatment outcomes in psychiatry
Chekroud, A. M., Bondar, J., Delgadillo, J., Doherty, G., Wasil, A., Fokkema, M., Cohen, Z., Belgrave, D., DeRubeis, R., Iniesta, R., et al. (2021) · World Psychiatry · doi:10.1002/wps.20882 · Cited by 531
Self-citationBuckman, J. E. J., Underwood, A., Clarke, K., Saunders, R., Hollon, S. D., Fearon, P., & Pilling, S. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.07.005 · Cited by 398
“Interestingly, a review of four ADM discontinuation RCTs using the individual patient data from those studies (n=1462) found no prognostic effect of a history of prior episodes across the dataset, irrespective of the number of prior episodes (Gueorguieva et al., 2017).”
BackgroundInfluentialKetamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
Self-citationModern views of machine learning for precision psychiatry
Chen, Z. S., Kulkarni, P. (., Galatzer-Levy, I. R., Bigio, B., Nasca, C., & Zhang, Y. (2022) · Patterns · doi:10.1016/j.patter.2022.100602 · Cited by 210
Metadata
- Authors
- Gueorguieva, R., Chekroud, A. M., & Krystal, J. H.
- Affiliations
- Yale University (US)
- Yale New Haven Hospital (US)
- Corresponding author
- Gueorguieva, Ralitza
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 4
- Issue
- 3
- Pages
- 230-237
- ISSN
- 2215-0366 (ISSN-L)
- PMC
- PMC5340978
- OpenAlex
- W2586756570
- Cited by
- 67
- References
- 36
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 13 · 2022: 6 · 2021: 7 · 2020: 7 · 2019: 5 · 2018: 6 · 2017: 3
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion, cc-by)
- PubMed Central (acceptedVersion, cc-by)
- Funders
- National Institutes of Health (grants K05AA14906 and 2P50AA012870)
- National Center for Research Resources [NCRR] (grant UL1RR024139)
- National Center for Advancing Translational Science [NCATS] (grant 5UL1TR000142)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, relapse, antidepressant discontinuation, duloxetine, fluoxetine, treatment continuation, depression severity, relapse prevention, predictors of relapse, individual patient data meta-analysis
- MeSH terms
- Duloxetine Hydrochloride, Adult, Antidepressive Agents, Major Depressive Disorder, Female, Fluoxetine, Humans, Male, Middle Aged, Patient Dropouts, Recurrence, Severity of Illness Index, Time Factors, Meta-Analysis as Topic, Placebo Effect, Treatment Outcome, Withholding Treatment, Protective Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. https://app.cochat.ai/papers/10.1016/s2215-0366(17)30038-x
- The paper
- Gueorguieva, R., Chekroud, A. M., & Krystal, J. H. (2017). Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(17)30038-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
